Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL
Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.
Rajat Bannerji, MD, PhD, of the Rutgers Cancer Institute of New Jersey discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma (NCT0229095).
The first-in-human phase one study is to determine the safety, tolerability, and appropriate dosage of odronextamab. The dose-escalation portion of the study is complete with results having been presented at the American Society of Hematology (ASH) Annual Meeting & Exposition 2019.
Researchers presented longer follow-up data at ASH 2020 on durable response rates and ongoing remission. According to the study, an overall response rate of 55% was achieved with all patients achieving a complete response. Of those who responded, 83% were durable responses, meaning response lasted at least 3 months. At the time of data cutoff, 1 patient had a durable response of 21 months.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
